10/10/2013 7:56:40 AM
by Richard Daverman, PhD
October 9, 2013 -- ASLAN Pharmaceuticals of Singapore completed a Series B financing that brought in $22 million, led by new investor Cenova Ventures of Shanghai and joined by two other new investors: Morningside Group and XinChen Ventures. Existing investors BioVeda Capital and Sagamore Bioventures also participated in the round. ASLAN in-licenses drugs that are at or near clinical trial stage, and then brings them through Phase II proof-of-concept, at which point the company plans to partner its drugs. More details....
Help employers find you! Check out all the jobs and post your resume.
comments powered by